Stage III Ovarian Cancer AJCC v8 (DBCOND0106672)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06630325	A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced, Recurrent Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer	Abemaciclib Carboplatin Doxorubicin Exemestane Fulvestrant Gefitinib Gemcitabine Letrozole Olaparib Osimertinib Paclitaxel Pemetrexed Tamoxifen Temozolomide Tetracycline	treatment	2	not_yet_recruiting
NCT04314401	National Cancer Institute "Cancer Moonshot Biobank"	No drug interventions	Not Available	Not Available	recruiting
NCT04514484	Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	Cabozantinib Nivolumab	treatment	1	active_not_recruiting
NCT04550494	Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations	Talazoparib	treatment	2	recruiting
NCT05092373	Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax	Albumin human Atezolizumab Cabozantinib Paclitaxel	treatment	1	recruiting
NCT03428802	Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability	Pembrolizumab	treatment	2	recruiting
NCT03784677	A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors	Calcium SOR-C13	treatment	1	completed
NCT04616534	Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors	Elimusertib Gemcitabine	treatment	1	active_not_recruiting
NCT02650986	Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1	Cyclophosphamide Decitabine Lifileucel	treatment	1 / 2	active_not_recruiting
NCT03907527	Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer	No drug interventions	treatment	1	active_not_recruiting
NCT05039801	IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors	Bevacizumab Capivasertib Paclitaxel	treatment	1	recruiting
NCT04095364	Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Carboplatin Letrozole Paclitaxel	treatment	3	recruiting
NCT05415709	Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer	Carboplatin Chloride ion Cisplatin Paclitaxel Platinum	treatment	0	recruiting
NCT05786456	e-Health Intervention (Day-by-Day) for the Management of Fear of Progression in Women With Stage III or IV Gynecologic Cancer: A Pilot Study	No drug interventions	supportive_care	Not Available	recruiting
NCT05733000	CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors	Devimistat Fluorouracil Gemcitabine Hydroxychloroquine Lipoic acid	treatment	2	recruiting
NCT04491942	Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer	Chloride ion Cisplatin Elimusertib Gemcitabine Platinum	treatment	1	active_not_recruiting
NCT05368506	ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer	Azenosertib	treatment	0	withdrawn
NCT04501913	Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes	No drug interventions	Not Available	Not Available	active_not_recruiting
NCT03606486	Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer	No drug interventions	diagnostic	Not Available	terminated
NCT04794322	Developing a Test for the Detection of Ovarian Cancer	No drug interventions	Not Available	Not Available	recruiting
NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	Dostarlimab Niraparib	treatment	1	recruiting
NCT03707574	Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study	No drug interventions	Not Available	Not Available	active_not_recruiting
NCT05238831	SMMART Adaptive Clinical Treatment (ACT) Trial	Albumin human Alectinib Alpelisib Anastrozole Atezolizumab Bevacizumab Capecitabine Carboplatin Cobimetinib Entrectinib Eribulin Fulvestrant Hyaluronidase (human recombinant) Irinotecan Letrozole Niraparib Olaparib Paclitaxel Palbociclib Pertuzumab Trastuzumab Trastuzumab emtansine Vemurafenib Vinorelbine Vismodegib	treatment	0	withdrawn
NCT05276973	Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer	Carboplatin Ipatasertib Paclitaxel	treatment	1	recruiting
NCT03943173	Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery	Olaparib	treatment	0	active_not_recruiting
NCT04067960	Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer	No drug interventions	screening	0	completed
NCT03735589	Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Benzalkonium	treatment	1 / 2	withdrawn
NCT03939481	Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer	No drug interventions	Not Available	Not Available	active_not_recruiting